Ensysce Reports Q3 2026 Results and Buys Cy Biopharma
The company reported strengthened cash reserves and announced the acquisition of Cy Biopharma to support its CRPS drug pipeline.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed